Jason Shafrin, PhD

We Have Vaccines, Now What? How to Ensure Continued COVID-19 Vaccine Discovery and Expedite Access

02/22/2021

Jason Shafrin, PhD

Marlon Graf, PhD

Rifat Tuly, MPH

Christoph Glaetzer, Dipl Kfm

Stacey Hickson, PhD

T Joseph Mattingly II, PhD, PharmD, MBA

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has resulted in a catastrophic burden in both health and economic costs. Despite the December 2020 emergency use authorizations of two COVID-19 vaccines,...

...

02/22/2021

Journal of Clinical Pathways

Perspectives

COVID-19 Pandemic Vindicates the ISPOR Value Flower

06/17/2020

Jason Shafrin, PhD

Kathy Lang, PhD

Ross Maclean, MD

Abstract: What is the right price for a new treatment for COVID-19? One common approach—which is frequently used worldwide and in the United States by the Institute of Clinical and Economic Review—measures treatment...

...

06/17/2020

Journal of Clinical Pathways

Counterpoint

Making Precision Benefit Design Patient-Centered

09/13/2018

Jason Shafrin, PhD

Precision benefit design is an extension of the concept of value-based insurance design (VBID), which aims to link patient benefit design and coinsurance to the likely benefit of a treatment net of its cost. Whereas...

...

09/13/2018

Journal of Clinical Pathways